<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00781846</url>
  </required_header>
  <id_info>
    <org_study_id>8669-010</org_study_id>
    <secondary_id>AP23573-08-111</secondary_id>
    <nct_id>NCT00781846</nct_id>
  </id_info>
  <brief_title>Trial of Deforolimus in Combination With Bevacizumab for Patients With Advanced Cancers (8669-010)(COMPLETED)</brief_title>
  <official_title>A Phase I Trial of Oral Deforolimus (AP23573; MK-8669), an mTOR Inhibitor, in Combination With Bevacizumab for Patients With Advanced Cancers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ariad Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the safety, tolerability, and recommended phase 2 dose&#xD;
      of oral ridaforolimus administered in combination with intravenous bevacizumab in patients&#xD;
      with advanced cancers.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2008</start_date>
  <completion_date type="Actual">February 2010</completion_date>
  <primary_completion_date type="Actual">February 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Identification of recommended phase 2 dose of ridaforolimus in combination with bevacizumab</measure>
    <time_frame>Duration of the trial</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Characterize the overall safety and tolerability of ridaforolimus in combination with bevacizumab</measure>
    <time_frame>Duration of the study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Description of the anti-tumor activity of ridaforolimus in combination with bevacizumab</measure>
    <time_frame>Duration of the study</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">17</enrollment>
  <condition>Solid Tumor</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>30mg QDx5/wk ridaforolimus plus 10mg/kg Q2wks bevacizumab for 4 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>40mg QDx5/wk ridaforolimus plus 10mg/kg Q2wks bevacizumab for 4 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>40mg QDx5/wk ridaforolimus plus 15mg/kg Q3wks bevacizumab for 3 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ridaforolimus</intervention_name>
    <description>oral tablets, daily for 5 days/week</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>3</arm_group_label>
    <other_name>deforolimus</other_name>
    <other_name>AP23573</other_name>
    <other_name>MK-8669</other_name>
    <other_name>ridaforolimus was also known as deforolimus until May 2009</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bevacizumab</intervention_name>
    <description>IV infusion</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>3</arm_group_label>
    <other_name>avastin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  18 years of age or older&#xD;
&#xD;
          -  Advanced or metastatic solid tumor malignancy&#xD;
&#xD;
          -  ECOG performance status of less than or equal to 1&#xD;
&#xD;
          -  Life expectancy of greater than 3 months&#xD;
&#xD;
          -  At least 4 weeks must have elapsed between prior investigational therapy,&#xD;
             chemotherapy, or radiotherapy, and the first dose of deforolimus&#xD;
&#xD;
          -  Adequate hematological, hepatic and renal function&#xD;
&#xD;
          -  Serum cholesterol less than or equal to 350 mg/dL and triglycerides less than or equal&#xD;
             to 400 mg/dL&#xD;
&#xD;
          -  Signed informed consent&#xD;
&#xD;
          -  Women of childbearing potential must have a negative serum pregnancy test within 7&#xD;
             days of starting therapy and must use an approved contraceptive method from time of&#xD;
             screening until 30 days after the last dose of study drug&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Tumor location in close proximity to a major blood vessel&#xD;
&#xD;
          -  History of brain metastases, spinal cord compression, or carcinomatous meningitis.&#xD;
             Primary brain tumors (for example, glioblastoma) are allowed.&#xD;
&#xD;
          -  New brain metastases, spinal cord compression, or leptomeningeal metastases on&#xD;
             screening CT scan or MRI&#xD;
&#xD;
          -  Hemoptysis or hematemesis within 28 days prior to entering the trial&#xD;
&#xD;
          -  Clinical significant unexplained bleeding within 28 days prior to entering the trial&#xD;
&#xD;
          -  Uncontrolled hypertension&#xD;
&#xD;
          -  Proteinuria at screening&#xD;
&#xD;
          -  Clinically significant cardiovascular disease&#xD;
&#xD;
          -  Newly diagnosed or poorly controlled type 1 or 2 diabetes&#xD;
&#xD;
          -  Active infection requiring prescribed intervention&#xD;
&#xD;
          -  Other concurrent illness that, in the Investigator's judgement, would either&#xD;
             compromise the patient's safety or interfere with the evaluation of the safety of the&#xD;
             study drug&#xD;
&#xD;
          -  Major surgery within 28 days before trial entry, or any incompletely healed surgical&#xD;
             incision; minor surgery or procedures within 7 days&#xD;
&#xD;
          -  Pregnant or breastfeeding&#xD;
&#xD;
          -  Known allergy to macrolide antibiotics&#xD;
&#xD;
          -  Known hypersensitivity to any component of bevacizumab&#xD;
&#xD;
          -  Concurrent treatment with medications that strongly induce or inhibit cytochrome P450&#xD;
             (CYP3A)&#xD;
&#xD;
          -  Known history of HIV sero-positivity&#xD;
&#xD;
          -  Any condition in the Investigator's judgement that renders the patient unable to fully&#xD;
             understand and provide informed consent and/or comply with the protocol&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Frank Haluska, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Ariad Pharmaceuticals</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <results_reference>
    <citation>Nemunaitis J, Hochster HS, Lustgarten S, Rhodes R, Ebbinghaus S, Turner CD, Dodion PF, Mita MM. A phase I trial of oral ridaforolimus (AP23573; MK-8669) in combination with bevacizumab for patients with advanced cancers. Clin Oncol (R Coll Radiol). 2013 Jun;25(6):336-42. doi: 10.1016/j.clon.2013.02.005. Epub 2013 Apr 21.</citation>
    <PMID>23615181</PMID>
  </results_reference>
  <verification_date>February 2015</verification_date>
  <study_first_submitted>October 28, 2008</study_first_submitted>
  <study_first_submitted_qc>October 28, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 29, 2008</study_first_posted>
  <last_update_submitted>February 12, 2015</last_update_submitted>
  <last_update_submitted_qc>February 12, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 13, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sirolimus</mesh_term>
    <mesh_term>Bevacizumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

